cas 141-30-0|| where to buy 3,6-Dichloropyridazine

Nombre del producto:3,6-Dichloropyridazine

IUPAC Name:3,6-dichloropyridazine

Unidad de embalaje	Stock disponible	Precio($)
CM102266-500g	in stock	ƅƅ
CM102266-1000g	in stock	ňǕǕ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Notas adicionales

Verification code*

refresh

: Núm. De CAS :141-30-0; Fórmula molecular:C4H2Cl2N2; Punto de fusión:-; Código de sonrisas:ClC1=NN=C(Cl)C=C1; Densidad:

: Número de catálogo:CM102266; Peso molecular:148.97; Punto de ebullición:; Nº Mdl:MFCD00006466; Almacenamiento:Store at 2-8°C.

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Resmetirom; Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis.
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD).
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.